FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 151 filers reported holding FATE THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 1.11 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $21,456,000 | -18.7% | 362,000 | +19.1% | 0.42% | -10.7% |
| Q2 2021 | $26,384,000 | +5.3% | 304,000 | 0.0% | 0.47% | -11.0% |
| Q1 2021 | $25,065,000 | -51.1% | 304,000 | -46.1% | 0.53% | -48.0% |
| Q4 2020 | $51,291,000 | +92.1% | 564,067 | -15.6% | 1.01% | +56.0% |
| Q3 2020 | $26,703,000 | -14.8% | 668,067 | -26.9% | 0.65% | -28.8% |
| Q2 2020 | $31,352,000 | -12.7% | 913,775 | -43.5% | 0.91% | -19.9% |
| Q1 2020 | $35,913,000 | -8.4% | 1,616,993 | -19.3% | 1.14% | -8.8% |
| Q4 2019 | $39,191,000 | +29.2% | 2,002,605 | +2.5% | 1.25% | +1.1% |
| Q3 2019 | $30,328,000 | -12.3% | 1,952,897 | +14.7% | 1.24% | -0.5% |
| Q2 2019 | $34,569,000 | +15.5% | 1,702,897 | 0.0% | 1.24% | +8.3% |
| Q1 2019 | $29,920,000 | +40.9% | 1,702,897 | +2.9% | 1.15% | +34.9% |
| Q4 2018 | $21,232,000 | +11.1% | 1,654,865 | +41.0% | 0.85% | +24.1% |
| Q3 2018 | $19,118,000 | – | 1,173,617 | – | 0.68% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
| Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
| Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
| DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
| Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
| Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
| Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
| Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
| Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |